ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGL Angle Plc

11.00
0.50 (4.76%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 4.76% 11.00 10.50 11.50 11.25 10.50 10.50 739,064 15:49:55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 2.19M -20.13M -0.0624 -1.76 33.88M
Angle Plc is listed in the Business Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 10.50p. Over the last year, Angle shares have traded in a share price range of 7.25p to 37.50p.

Angle currently has 322,641,668 shares in issue. The market capitalisation of Angle is £33.88 million. Angle has a price to earnings ratio (PE ratio) of -1.76.

Angle Share Discussion Threads

Showing 33226 to 33245 of 33275 messages
Chat Pages: 1331  1330  1329  1328  1327  1326  1325  1324  1323  1322  1321  1320  Older
DateSubjectAuthorDiscuss
13/12/2024
09:17
Yasx, your time is running out. You'll crawl back under your rock soon enough.
atmysignal
13/12/2024
08:52
However, we can expect more studies and spin - these come naturally to AN
yasx
13/12/2024
08:49
So it appears we will end the year with no further progress with AZ (very concerning) and no new deals with any other household name as was claimed months ago.
yasx
12/12/2024
21:08
Ohwhatfun, which part of your lobe are you using when you post?
atmysignal
12/12/2024
12:10
Odd action.!!!

Further revenue miss warning news pending?

ohwhatfun
12/12/2024
12:05
ref sawney..

I was hoping for a bit more than 'just another presentation'.

htrocka2
12/12/2024
10:14
hxxps://x.com/Parsortix/status/1867143584022954306
sawney
11/12/2024
19:37
Still no news on the next phase of the Astra deal - starting to seem like dust vanishing in the air on a windy day.
yasx
10/12/2024
16:26
186k buy just now
atmysignal
10/12/2024
15:27
Many are buys
atmysignal
10/12/2024
15:16
A day of sells today it seems. Price has held up well.
narutodono
09/12/2024
09:49
He was sent one of those little toy models by VRS. Pride and joy for him
atmysignal
08/12/2024
15:05
Very disrespectful way to talk about PWhite who is still clearly suffering PTSD from his experience losing 99% of his cash on VRS
thiopia
08/12/2024
14:16
Has this dog not been put down yet
havinthelasttoast
06/12/2024
16:10
I note RXRX is pushing hard today - Surprised this has 'not' been mentioned:• https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-studyThe DAHLIA trial involves assessing REC-1245 for its impact on DNA Damage Response (DDR) pathways and cell cycle checkpoints, targeting a biomarker-enriched population.• https://ir.recursion.com/node/11041/pdfNOTE - Based on an as of yet undisclosed specific set of biomarkers, Recursion estimates that the initially addressable population for this potential therapeutic to be >100,000 patients in the US and EU5.-AGL:• By analysing biomarkers like phosphorylated histone variant H2AX (?H2AX) or phosphorylated KRAB-associated protein 1 (pKAP1) in CTCs - AGL could provide insights into how effectively REC-1245 induces DNA damage and disrupts DDR networks.https://angleplc.com/laboratory-services/dna-damage-response-ddr/• CTC analysis can help confirm RBM39 degradation and its downstream effects on CDK12-like phenotypes in DDR modulation, offering data on functional and molecular impacts, particularly in refractory or relapsed cancer cases.-AGL + (AI) RXRX:Recursion's AI-powered maps of biology focus on high-throughput biological data analysis. AGL 'could' contribute:• RAW DATA for AI modeling - CTC derived molecular and functional data could be integrated into Recursion's AI platform, enhancing the identification of relationships between biomarkers and drug response.• VALIDATION of AI predictions - AGL 'could' validate Recursion's AI-predicted biomarkers in real-world samples, improving the precision of treatment response predictions.-AGL + RXRX + NuPROBE:The integration of AGLs DDR assay with NuProbe's DNA panel (which may identify DDR-related mutations, such as in CDK12) could enable:• Comprehensive monitoring of REC-1245's effects.• ?Dual functional-genomic profiling of patients' tumors to refine response predictions and treatment pathways.https://www.londonstockexchange.com/news-article/AGL/exclusive-agreement-for-dna-ngs-panel/16677437-Back to sleep zzz
5oletrader
06/12/2024
13:24
Besides conspiracy theories, do you have anything to say about the progress of Angle.
And
30p
30p
30p
30p

bobbie121
06/12/2024
10:27
Could bobbie be that loon adw trying to FUD everyone into selling into 7.5p bid not that long ago?Passive aggressive subtle deramp style a big giveaway imo
atmysignal
06/12/2024
10:09
Millwallfan,because we have been able to do (1) for a long time, but has anybody been able to do (2) in even a single case?
bobbie121
06/12/2024
09:41
What moon landing?
muffster
06/12/2024
09:40
Do you also believe that the moon landing was faked?
bobbie121
Chat Pages: 1331  1330  1329  1328  1327  1326  1325  1324  1323  1322  1321  1320  Older

Your Recent History

Delayed Upgrade Clock